REDUCTION OF BRAIN INJURY USING HEPARIN TO INHIBIT LEUKOCYTE ACCUMULATION IN A RAT MODEL OF TRANSIENT FOCAL CEREBRAL-ISCHEMIA .2. DOSE-RESPONSE EFFECT AND THE THERAPEUTIC WINDOW
K. Yanaka et al., REDUCTION OF BRAIN INJURY USING HEPARIN TO INHIBIT LEUKOCYTE ACCUMULATION IN A RAT MODEL OF TRANSIENT FOCAL CEREBRAL-ISCHEMIA .2. DOSE-RESPONSE EFFECT AND THE THERAPEUTIC WINDOW, Journal of neurosurgery, 85(6), 1996, pp. 1108-1112
The administration of massive doses of heparin has been demonstrated t
o reduce reperfusion injury. The authors have found that heparin's ant
ileukocyte adhesion property may play a more important role than its a
nticoagulant property in preventing ischemia and reperfusion injury. A
lthough the administration of massive doses of heparin has been demons
trated to reduce brain injury ischemia and reperfusion, the optimum do
sage and timing for heparin administration remain unknown. The purpose
of this study was to evaluate the dose-response effect and determine
the time during which heparin must be administered to inhibit leukocyt
e accumulation, reduce infarct size, and improve neurological outcome
in rats subjected to 1 hour of cerebral ischemia and 48 hours of reper
fusion. Forty-nine animals were included in the study. The animals rec
eiving commercial unfractionated heparin at a total dose of 2.67 to 4
mg/kg showed a significant inhibition of leukocyte accumulation, reduc
ed infarct size, and lessened neurological dysfunction 48 hours after
reperfusion (p<0.05) when compared to untreated animals. The animals r
eceiving unfractionated heparin within 3 hours after reperfusion also
showed significantly better results than untreated animals. These indi
cate that standard doses of heparin prevent reperfusion injury, and re
latively late postischemic administration of heparin also is effective
in brain protection. These findings may have therapeutic potential as
an adjunct to thrombolytic therapy and possibly for other prefusion d
eficiencies with leukocyte-endothelial interaction. In view of these e
ncouraging experimental findings, the clinical application of heparin
administration after ischemia and reperfusion warrants serious conside
ration.